Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Author

S. Dell'Aniello

S. Alessi-Severini

Keywords

Canada/epidemiology

*Diabetes Mellitus, Type 2/drug therapy/epidemiology

*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use

Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use

Glucagon-Like Peptide 1

Glucagon-Like Peptide-1 Receptor/agonists

Hypoglycemic Agents/pharmacology/therapeutic use

*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

*Symporters/therapeutic use

United Kingdom/epidemiology

Type 2 diabetes

dipeptidyl peptidase 4 inhibitors

glucagon-like peptide 1 receptor agonists

sodium-glucose co-transporter 2 inhibitors

not involving SGLT-2 inhibitors or DPP-4 inhibitors.

Year of Publication

2022

Journal

BMC Endocr Disord

Volume

22

Number of Pages

241

ISBN Number

1472-6823

Accession Number

36175881

DOI

10.1186/s12902-022-01140-1